Quantum Pharmaceuticals enters collaboration with Children's Cancer Institute Australia

Moscow, October, 28 2008

Quantum Pharmaceuticals announce drug discovery collaboration with Children's Cancer Institute Australia's (CCIA). Under the terms of the agreement Quantum Pharmaceuticals gets access to CCIA in-house disease target data. Quantum Pharmaceuticals will contribute its technological breakthroughs and expertise in small molecule drug discovery to feed the portfolio of CCIA with new drug candidates. CCIA is to further develop the discovered inhibitors. The targets and financial terms were not disclosed.

About Quantum Pharmaceuticals

Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.

About CCIA

Children's Cancer Institute Australia's (CCIA) vision is to save the lives of all children with cancer and eliminate their suffering.Our mission is to be a leader in preventing cancer, to find new ways of curing cancer in children through world-class research, to ensure the best possible quality of life for these children and their families, to share the vision with others and to increase awareness, participation and funding.

Quantum Pharmaceuticals collaborates with University of Pittsburgh on HIV drug discovery.

Moscow, October, 20 2008

Quantum Pharmaceuticals and University of Pittsburgh announced a drug discovery collaboration in HIV sphere. Under the terms of agreement Quantum Pharmaceuticals gets access to the target data from University of Pittsburgh. Quantum Pharmaceuticals will apply its industry leading computational technology to discover novel small molecule inhibitors for this target. The University is to provide biological expertise and further develop the discovered inhibitors. The financial terms of the deal were not disclosed.
About Quantum Pharmaceuticals
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
About University of Pittsburgh
Founded in 1787 the University of Pittsburgh has evolved into an internationally recognized center of learning and research. The University’s 12,000 employees, including 3,800 full-time faculty members, serve about 34,000 students through the programs of 15 undergraduate, graduate, and professional schools.

Quantum Pharmaceuticals announce collaboration with University of Colorado at Boulder

Moscow, July 15 2008
Quantum Pharmaceuticals announce drug discovery collaboration with University of Colorado at Boulder. Under the terms of agreement Quantum Pharmaceuticals will apply its state-of-the-art in-house drug discovery technology to discover novel small molecule inhibitors in inflammation area. CU-Boulder is to further develop the discovered inhibitors. The targets and financial terms were not disclosed.
About Quantum Pharmaceuticals
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
About CU-Boulder
As the flagship university of the state of Colorado, CU-Boulder is a dynamic community of scholars and learners. As one of 34 U.S. public institutions belonging to the prestigious Association of American Universities (AAU) – and the only member in the Rocky Mountain region – we have a proud tradition of academic excellence, with four Nobel laureates and more than 50 members of prestigious academic academies. CU-Boulder has blossomed in size and quality since we opened our doors in 1877 – attracting superb faculty, staff, and students and building strong programs in the sciences, engineering, business, law, arts, humanities, education, music, and many other disciplines. Today, with our sights set on becoming the standard for the great comprehensive public research universities of the new century, we strive to serve the people of Colorado and to engage with the world through excellence in our teaching, research, creative work, and service.

Quantum Pharmaceuticals and Tibotec Pharmaceuticals enter antiviral drug discovery collabortaion.

Quantum Pharmaceuticals announces a drug discovery collaboration with Tibotec Pharmaceuticals (subsidiary of Johnson & Johnson).

Under the terms of the agreement Quantum Pharmaceuticals will provide Tibotec Pharmaceuticals with the family of anti-viral drug hits. The drug hits were discovered by Quantum Pharmaceuticals using its proprietary discovery technology. Tibotec Pharmaceuticals is to further evaluate and develop transferred molecules. Financial terms of the collaboration were not disclosed.

About Tibotec Pharmaceuticals BVBA
Tibotec BVBA is a global pharmaceutical and research development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, Pa. and Cork, Ireland. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS and hepatitis C drugs, and anti-infectives for diseases of high unmet medical need.

About Quantum Pharmaceuticals
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.

Quantum Pharmaceuticals and Otechestvennye Lekarstva OJSC entered drug discovery collaboration.

(Moscow, 25 March 2008) Quantum Pharmaceuticals entered a collaboration with Otechestvennye Lekarstva OJSC. Under the terms of collaborative agreement Quantum Pharmaceuticals will apply its proprietary technology to explore the mechanism of action and new therapeutic uses of several compounds of Otechestvennye Lekarstva OJSC. Quantum Pharmaceutical will utilize its proprietary protein panel representative for human proteome. The financial terms of the agreement were not disclosed.

About Quantum Pharmaceuticals

Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.

About Otechestvennye Lekarstva OJSC
Otechestvennye Lekarstva OJSC is one of the largest Russian pharmaceutical companies with recent turnover of US$150 million. The company has 5,000 employees and markets over 200 products in Russia and in 20 other countries. Otechestvennye Lekarstva OJSC was selected as the best pharmaceutical company in Russia in 2005 and 2006 by the Russian government.

LEADFINDING.COM, ONLINE HIT-TO-LEAD OPTIMIZATION SERVICE

San Diego, California – December 17th, 2007 – ChemDiv Inc (San Diego) and Quantum Pharmaceuticals (Moscow) announce the launch of LEADFINDING.COM, their powerful new internet-based hit-to-lead optimization service and online chemistry store.
LEADFINDING.COM brings together, the industry leading computational chemistry software from Quantum Pharmaceuticals and ChemDiv’s world’s largest and most diverse small molecule collection for drug discovery. Fully automated web-based interface predicts binding affinities on the fly, facilitating basic hit-to-lead optimization tasks for a wide audience of researchers.
LEADFINDING.COM will be of special interest to academic and biotech researchers who have identified a small molecule hit and wish to deploy LEADFINDING.COM’s expertise in selecting candidate molecules for hit follow-up. We offer an online hit-to-lead service helping identify novel chemical lead series from ChemDiv world’s largest Discovery Collection of small molecules. LEADFINDING.COM provides unique online computational tools including hit analog searches, physiochemical properties filters, and predictions of biological activity (IC50). Availability of all selected molecules can be confirmed for online purchase and immediate delivery.
About LEADFINDING:
LEADFINDING is a joint project of ChemDiv, Inc. (ChemDiv) and Quantum Pharmaceuticals (Quantum). The project is resulting from Quantum’s effort in bringing the power of their computational models to the world life sciences community and ChemDiv’s conceptual approach to modern day discovery process. ChemDiv has been constantly contributing to the evolution of drug discovery roadmap, most recently by introducing the Chemistry Anywhere™ concept. Chemistry Anywhere™ is ChemDiv’s partnering program which by accessing a variety of online research tools shortens the time from design to wet lab results.
About ChemDiv:
ChemDiv ( www.chemdiv.com ) is a global chemistry-driven contract research organization. ChemDiv is focused on identifying and delivering pre-clinical opportunities and services to life science partners for the treatment of life-threatening diseases. Over 17 years ChemDiv provides Discovery outSourceTM solutions including medicinal and synthetic chemistry, pre-clinical development, screening libraries and global logistics. ChemDiv international research team encompasses 550 chemists and biologists in San Diego and Moscow based R&D centers.
About Quantum Pharmaceuticals:
Quantum (www.q-pharm.com) develops and commercializes industry leading computational drug discovery technologies based on applying quantum, molecular and statistical physics in molecular modeling. Our solutions help pharmaceutical companies and research facilities around the world successfully accelerate the identification and optimization of new compounds that have the potential to become drug products.

EMD Serono, Inc licensed Quantum Pharmaceuticals’ drug discovery technology.

Moscow, 10 December, 2007

EMD Serono, Inc entered license agreement with Quantum Pharmaceuticals to get an access to Quantum Pharmaceuticals’ small molecule hit identification computational platform and apply it in in-house research.

The Quantum Pharmaceuticals’ industry leading computational drug design technologies is based on applying quantum, molecular and statistical physics in molecular modeling and was successfully applied in different drug discovery projects. The initial term of the agreement is one year. The financial terms of the agreement were not disclosed.

Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.

EMD Serono, Inc. and Merck Serono S.A. are affiliates of Merck KGaA, Darmstadt, Germany, with over 16,000 employees worldwide and a strong presence on all continents.

Quantum Pharmaceuticals and MOLECMO Nanobiotechnologies announce collaboration.

Moscow, Russia (August, 13 2007) -Quantum Pharmaceuticals announced today a collaboration with MOLECMO Nanobiotechnologies, a drug discovery company.
The collaboration is aimed at application of Quantum Pharmaceuticals' industry leading technology to anti-viral drug discovery project led by MOLECMO. The financial terms of the agreement were not disclosed.
About Quantum Pharmaceuticals.
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.
About MOLECMO.
MOLECMO is an antiviral drug discovery company based in Cambridge, Massachusetts in the heart of the biotechnology circle, proximal to world class research institutes like Harvard and MIT, famed Boston Hospitals and leading Pharmaceutical firms.

HIV-1 integrase drug discovery collaboration

Moscow, September, 28 2006

Quantum Pharmaceuticals and A.N. Belozersky Institute of Physico-Chemical Biology entered drug discovery collaboration aimed to discovery of novel small molecule inhibitors of HIV-1 integrase. HIV-1 integrase is one of the most promising targets in HIV drug discovery. Under the terms of the agreement Quantum Pharmaceuticals will apply its indystry leading drug discovery technology platform to identify novel classess of HIV-1 integrase inhibitors. The Institute is to evaluate the discovered compounds and contribute into its further research and development.

About Quantum Pharmaceuticals
Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.

Quantum Pharmaceuticals and Institute of Pulmonology entered COPD drug discovery collaboration.

Moscow, June, 18 2006 Quantum Pharmaceuticals and Federal State Institution "Scientific Research Institute of Pulmonology of Roszdrav" entered COPD collaboration.

Quantum Pharmaceuticals and Federal State Institution "Scientific Research Institute of Pulmonology of Roszdrav» announced drug discovery collaboration. The collaboration is aimed on the application of Quantum Pharmaceuticals’ proprietary drug discovery technology to identify novel small molecules inhibitors of Human Neutrophil Elastase.

Under the terms of agreement Institute will be responsible for biological evaluation and further development of discovered inhibitors.


About Quantum Pharmaceuticals.

Quantum Pharmaceuticals is a drug discovery company based in Moscow, Russia specializing in small molecule screening and design through the use of its proprietary technology platform.